Czaja A J, Sievers C, Zein N N
Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Dig Dis Sci. 2000 May;45(5):1028-35. doi: 10.1023/a:1005506031717.
To assess the relationship between serum cytokine behavior and treatment outcome in type 1 autoimmune hepatitis, serum levels of interferon-gamma, interleukin-2, interleukin-4, and interleukin-10 were measured by enzyme immunoassay in 43 patients and 20 normal subjects. Serum samples were similarly tested in 38 patients after corticosteroid treatment. Serum levels of interleukin-2 and interleukin-4 were significantly lower in patients than in normal subjects. Interleukin-2 was the least common cytokine detected before (3%), during (0%), or after treatment (0%). Serum levels of interleukin-10 at presentation did not differ from those of normal subjects but they did decrease during therapy, especially in patients who entered remission. Changes in these levels, however, did not always parallel treatment outcome or histological activity. We conclude that serum levels of interleukin-2 and interleukin-4 are lower than normal in type 1 autoimmune hepatitis. Serum concentrations of interleukin-10 diminish during corticosteroid therapy but changes do not closely reflect outcome. The rarity of interleukin-2 in serum may be a distinguishing feature.
为评估1型自身免疫性肝炎患者血清细胞因子行为与治疗结果之间的关系，采用酶免疫分析法检测了43例患者和20名正常受试者血清中的γ干扰素、白细胞介素-2、白细胞介素-4和白细胞介素-10水平。对38例接受皮质类固醇治疗后的患者血清样本进行了类似检测。患者血清中白细胞介素-2和白细胞介素-4水平显著低于正常受试者。白细胞介素-2是治疗前（3%）、治疗期间（0%）或治疗后（0%）检测到的最不常见的细胞因子。就诊时白细胞介素-10血清水平与正常受试者无差异，但在治疗期间会下降，尤其是进入缓解期的患者。然而，这些水平的变化并不总是与治疗结果或组织学活性平行。我们得出结论，1型自身免疫性肝炎患者血清中白细胞介素-2和白细胞介素-4水平低于正常。皮质类固醇治疗期间白细胞介素-10血清浓度降低，但变化并不能密切反映治疗结果。血清中白细胞介素-2的罕见性可能是一个显著特征。
